Serp-1 for the Treatment of Acute Coronary Syndrome
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation
MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours
before admission and greater than 0.05 mV of presumed new ST-segment depression in at least 2
contiguous ECG leads OR, angina and per confirmatory angiogram, has been scheduled for
percutaneous coronary angioplasty. The primary objective of this study is to evaluate the
safety of Serp-1 injection when administered in 3 daily doses to patients undergoing
conventional therapy for Acute Coronary Syndrome (ACS) requiring early intervention.